Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1625 1633 1645 1646 1647
This examiner grants 0% of resolved cases
Dasia Ali Aldarondo has 3 resolved cases in Tech Center 1600. The allowance rate is 0.0% and the interview lift is 0.0%. The median days to allowance is 1459. This data for Art Unit 1600 is based on a very small sample of 3 cases. The 1459-day median is the primary timeline metric available. Practitioners should monitor these metrics as the case volume increases beyond 3 resolved cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18682785 | READY TO USE COMPOSITIONS OF CETRORELIX ACETATE | Non-Final OA | CITIBANK, N.A. |
| 18703963 | COMBINATION OF HUMAN NATURAL KILLER CELLS AND MACROPHAGES FOR CANCER THERAPY | Non-Final OA | The Regents of the University of California |
| 18568218 | ANTIBODIES THAT STIMULATE NK CELL-MEDIATED CYTOTOXICITY | Non-Final OA | The Regents of the University of California |
| 18281532 | TRANSPLANTED CELL PROTECTION VIA MODIFIED Fc RECEPTORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18292514 | COMBINATION THERAPY USING EXOSOME SECRETION INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | Non-Final OA | Research & Business Foundation SUNGKYUNKWAN UNIVERSITY |
| 18279848 | PERSONALIZED REDIRECTION AND REPROGRAMMING OF T CELLS FOR PRECISE TARGETING OF TUMORS | Final Rejection | The General Hospital Corporation |
| 18579227 | COMPOSITIONS AND METHODS FOR TREATING ALPHA-SYNUCLEINOPATHIES | Non-Final OA | The Johns Hopkins University |
| 18685103 | COMBINATION DRUG | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18570530 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | Non-Final OA | SPINALCYTE LLC |
| 18568011 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM) | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 18547627 | METHODS FOR EXPANDING REGULATORY T CELLS | Final Rejection | KSQ THERAPEUTICS, INC. |
| 18455544 | COMBINATION THERAPY OF SOLID TUMORS USING CHIMERIC ANTIGEN RECEPTOR CELLS REPRESENTING ADAPTIVE AND INNATE IMMUNITY | Non-Final OA | Regen Biopharma, Inc. |
| 18030754 | Camptothecin Derivative And Ligand-drug Conjugate Thereof | Non-Final OA | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy